SCHEMBL4612749

SCHEMBL4612749

CC(C)(C)OC(=O)N1CCN(c2ccc(-c3ccc(C(S)[C@H]4CCCC[C@@H]4C(=O)NCC#N)cc3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 10/20 0.53
CTSS P25774 8/20 0.53
CTSB P07858 8/20 0.51
GPR119 Q8TDV5 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
ALOX5 P09917 1/20 0.41
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
CTSL P07711 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4612844 0.84 CTSK (0.52) CTSKCTSSCTSBCTSL
SCHEMBL6136971 0.81 CTSK (0.53) CTSKCTSSCTSBALDH1A1CTSL
SCHEMBL4612687 0.81 CTSK (0.53) CTSKCTSSCTSBALDH1A1CTSL
SCHEMBL4612755 0.80 CTSK (0.58) CTSKCTSSCTSBCTSL
SCHEMBL4612752 0.80 CTSK (0.58) CTSKCTSSCTSBCTSL
SCHEMBL5685692 0.80 CTSK (0.58) CTSKCTSSCTSBGPR119PTPN2
SCHEMBL4991292 0.80 CTSK (0.58) CTSKCTSSCTSBGPR119PTPN2
SCHEMBL4698794 0.79 CTSK (0.53) CTSKCTSSCTSBGPR119SMN1; SMN2
SCHEMBL4613743 0.76 CTSK (0.46) CTSKCTSSCTSBCTSL
SCHEMBL4613012 0.75 CTSK (0.56) CTSKCTSSCTSBCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371747-B2 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA & CO. (CA) 2008-05-13 US claimed
EP-1446115-B1 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP claimed
US-20050014941-A1 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA LTD. (CA) 2005-01-20 US claimed
US-7371747-B2 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA & CO. (CA) 2008-05-13 US disclosed
EP-1446115-B1 CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP disclosed
US-20050014941-A1 Cyanoalkylamino derivatives as protease inhibitors MERCK FROSST CANADA LTD. (CA) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014941-A1 Cyanoalkylamino derivatives as protease inhibitors CTSB, CTSK, CTSS CTSK 2/4885CTSS 3/4885CTSB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.